What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary scientific interests are in Prostate cancer, Prostate, Surgery, Internal medicine and Prostatectomy.
His Prostate cancer research is multidisciplinary, incorporating elements of Randomized controlled trial and Urology.
His Prostate research is multidisciplinary, incorporating perspectives in Radiation therapy, Biopsy, Incidence, Pathology and Survival analysis.
Specifically, his work in Surgery is concerned with the study of Stage.
His research integrates issues of Patient satisfaction and Oncology in his study of Internal medicine.
His studies deal with areas such as Prostvac and Chills as well as Sipuleucel-T.
His most cited work include:
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (3775 citations)
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference (1831 citations)
- Consensus statement: Guidelines for PSA following radiation therapy (1040 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Prostate cancer, Internal medicine, Prostate, Oncology and Surgery.
The Prostate cancer study combines topics in areas such as Gynecology and Urology.
His research in the fields of Sipuleucel-T, Androgen and Randomized controlled trial overlaps with other disciplines such as In patient.
Paul F. Schellhammer interconnects Biopsy, Carcinoma, Pathology, Radiation therapy and Adenocarcinoma in the investigation of issues within Prostate.
His Oncology research incorporates themes from Clinical trial, Disease and Immunotherapy.
His studies in Surgery integrate themes in fields like Cystectomy, Quality of life, Radiology and Incidence.
He most often published in these fields:
- Prostate cancer (44.02%)
- Internal medicine (38.78%)
- Prostate (34.99%)
What were the highlights of his more recent work (between 2009-2021)?
- Prostate cancer (44.02%)
- Internal medicine (38.78%)
- Oncology (28.28%)
In recent papers he was focusing on the following fields of study:
Prostate cancer, Internal medicine, Oncology, Urology and Sipuleucel-T are his primary areas of study.
Paul F. Schellhammer combines subjects such as Quality of life, Surgery and Prostate with his study of Prostate cancer.
His work is dedicated to discovering how Surgery, Androgen suppression are connected with Clinical endpoint and other disciplines.
His Prostate study integrates concerns from other disciplines, such as Biopsy, Radiology and Penis.
His Oncology research integrates issues from Antiandrogens, Quartile, Castration resistant, Gynecology and Radiation therapy.
Paul F. Schellhammer has included themes like Immunotherapy, Asymptomatic, Proportional hazards model and Hazard ratio in his Sipuleucel-T study.
Between 2009 and 2021, his most popular works were:
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (3775 citations)
- Intermittent versus continuous androgen deprivation in prostate cancer. (345 citations)
- Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy (317 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His main research concerns Prostate cancer, Internal medicine, Urology, Oncology and Surgery.
His Prostate cancer research incorporates elements of Androgen and Hazard ratio.
He focuses mostly in the field of Hazard ratio, narrowing it down to topics relating to Proportional hazards model and, in certain cases, Prostate-specific antigen.
Paul F. Schellhammer works mostly in the field of Surgery, limiting it down to topics relating to Androgen suppression and, in certain cases, Clinical endpoint, Radiation therapy and Randomized controlled trial.
The concepts of his Sipuleucel-T study are interwoven with issues in Chills and Immunotherapy.
His work deals with themes such as Prostvac, Gastroenterology and Docetaxel, which intersect with Chills.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
